GW Pharmaceuticals, a Cambridge, UK-based biopharmaceutical company, has appointed Scott Giacobello as chief financial officer (CFO), reporting to Justin Gover, GW’s chief executive officer. Mr. Giacobello will be based at the company's US headquarters in Carlsbad, California. Related to this appointment, Adam George, GW's CFO since 2012, became managing director, UK, a newly-created executive role with responsibilities for UK operations. Mr. George will also report to Mr. Gover.
Scott Giacobello brings 25 years of finance and operational experience to GW. He most recently and until its acquisition by Allergan in late 2016, served as CFO for Chase Pharmaceuticals, a clinical-stage biopharmaceutical company focused on neurodegenerative disorders. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, most recently serving as vice president (VP) of finance for Global Research & Development. While at Allergan, he also served as VP of corporate finance and VP of Internal Audit & Compliance. Mr. Giacobello's previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young.
As Managing Director, UK, Mr. George will be responsible for UK operations including pipeline development, manufacturing scale-up, and European commercialization. Mr. George will continue as company secretary and will provide Mr. Giacobello support through the CFO transition.
Source: GW Pharmaceuticals